Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, shared on X:
“A project years ago that was met with difficulties in terms of recruitment but hoped to still answer important questions.
Prospective open-labelled phase 2 pembrolizumab in acral lentiginous melanoma confirming low response rates.
Thanks colleagues for supporting this effort.”
Title: Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian population
Authors: Herbert H Loong, Winnie Yeo, Candy Yuen, Frankie Mo, Tung Ching Chan, Kirsty W C Lee, Chiu Yan Chan, Ashley C Y Wong, Kenneth W C Wong, Daisy C M Lam, Joanna Tong, Carlos Wong
Other articles featuring Herbert Loong on OncoDaily.
